Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz Effect on Pyrotinib PK in Healthy Chinese Subjects
NCT04680091Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Nov 2020
- Primary completion
- Jan 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pyrotinib in HER2-positive breast cancer, sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration at Day 20, Area Under the Plasma Concentration-time Curve from 0 to last quantifiable concentration at Day 20 and 1 more. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04680091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680091.